Findings highlight the Pfizer-BioNTech vaccine’s role in preventing MIS-C, a rare post-COVID inflammatory syndrome in ...

Although it is seeing a downturn in sales and profits, German biotech BioNTech (Nasdaq: BNTX) is continuing to acquire assets ...

Unverified data about events after vaccinations is not evidence that the vaccine caused the event, as suggested in social ...

Recent health news highlights include Amgen addressing bone density concerns, AstraZeneca revising its financial outlook ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

In August, the Food and Drug Administration authorized updated vaccines against COVID-19. Here's what to know about the three ...

The Pfizer/BioNTech bivalent COVID-19 vaccine (Original and Omicron BA.4/BA.5) has the FDA’s EUA for use in individuals 5 years and over as a single booster dose administered at least two months ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Pfizer has been in an anomalous situation the last few years, to be sure, thanks to the pandemic. The vaccine developed with BioNTech and the viral protease inhibitor Paxlovid gave a huge boost to ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

In the third quarter of 2024, BioNTech and Pfizer executed the commercial launch of their variant-adapted COVID-19 vaccines for the 2024/2025 vaccination season. On July 3, 2024, BioNTech and Pfizer’s ...